Neuropathic pain

2 papers1 finding

Humans2

Associations

1

GLP-1 receptor agonists

downin humans1OR 0.32

1 study

GLP-1 receptor agonists lower the risk of neuropathic pain in humans (OR 0.32, 95% CI 0.15-0.65).
Humanstype 2 diabetes mellitusn = 500
Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes
Pain20 Aug 2026

More on GLP-1 receptor agonists

Trial sponsors

Pascoe Pharmazeutische Praeparate
Company1 trialPhase 212 people
GSK
Company1 trialPhase 148 people
Bial - Portela C
Company1 trialPhase 120 people
Michał Borys
1 trialPhase 4232 people
Barts & The London NHS Trust
1 trialPhase 4150 people
Cedars-Sinai Medical Center
1 trialPhase 4102 people
Universidade Federal de Santa Maria
1 trialPhase 437 people
Mahidol University
1 trialPhase 432 people

Latest

3 in 12 months

Frontiers in Pain ResearchYesterday

Metabolic and neuropathic outcomes following combined sodium-glucose cotransporter-2 inhibitor therapy and adjunctive acupuncture in obese patients with diabetic neuropathy: a case series

Trial in 3 peopleSGLT2 inhibitors

Pain28 Aug

Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes

Cross-sectional study of 500 peopleGLP-1 receptor agonists

Diabetes11 Aug

Accelerated Brain Aging in Type 1 Diabetes Across Painful and Painless Peripheral Neuropathy: MRI-Based Brain Age Estimates From Deep Learning

Cross-sectional study in peopleDiabetic peripheral neuropathy